Post by
lscfa on Dec 06, 2020 5:10pm
MD&A on sedar
In addition to the two patents granted in 2018, we have applied for a continuation patent on our US cannabinoid patent and have been issued the patent in Canada for “Methods of Treating Inflammatory Disorders and Global Inflammation with Compositions Comprising Phospholipid Nanoparticle Encapsulations of NSAIDs”. This new patent opens the door to discussions with pharmaceutical companies on how we may partner to develop and commercialize a line of NSAID-related products. Company has begun an investor relations campaign to ensure understanding of the need for R&D and more sustainable long-term growth to be our priority at this time. It will likely take us the better part of 18-24 months to establish the foundation, science and strong JV partnerships we need, yet we have a very promising future.